US Pharma MarketingThe post Taiho Oncology reports positive results in REZILIENT3 trial appeared first on Clinical Trials Arena.
Taiho Oncology reports positive results in REZILIENT3 trial
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported that the global Phase III REZILIENT3 trial assessing zipalertinib combined with platinum-based chemotherapy for the first-line treatment of certain NSCLC patients has achieved its primary endpoint. The post Taiho Oncology reports positive results in REZILIENT3 trial appeared first on Clinical Trials Arena .
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported that the global Phase III REZILIENT3 trial assessing zipalertinib combined with platinum-based chemotherapy for the first-line treatment of certain NSCLC patients has achieved its primary endpoint.
Source: Clinical Trials Arena